Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

ACEA 1021: flip or flop?

Margaret A Petty1, Philip M Weintraub, Kenneth I Maynard

  • 1CNS Pharmacology, Aventis Pharmaceuticals, Inc., JR2-303A, Bridgewater, NJ 08807-0800, USA. Margaret.petty@aventis.com

CNS Drug Reviews
|December 14, 2004
PubMed
Summary

Glycine site antagonism of the N-methyl-D-aspartate (NMDA) receptor offers a safer approach to blocking glutamate excitotoxicity. While ACEA 1021 shows promise, further human clinical data are needed to confirm its efficacy and safety.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enhancing Pharmacovigilance from the US Experience: Current Practices and Future Opportunities.

Drug safety·2021
Same author

An Update of the North American Chapter of the International Society of Pharmacovigilance (NASoP).

Drug safety·2021
Same author

Commentary on "Increase in cerebral blood flow indicated by increased cerebral arterial area and pixel intensity on brain magnetic resonance angiogram following correction of cervical lordosis".

Brain circulation·2019
Same author

Hormesis pervasiveness and its potential implications for pharmaceutical research and development.

Dose-response : a publication of International Hormesis Society·2011
Same author

Acute studies of a new primate model of reversible middle cerebral artery occlusion.

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association·2007
Same author

Biological stress response terminology: Integrating the concepts of adaptive response and preconditioning stress within a hormetic dose-response framework.

Toxicology and applied pharmacology·2007

Area of Science:

  • Neuroscience
  • Pharmacology

Background:

  • Glutamate excitotoxicity contributes to various neurological and psychiatric disorders.
  • NMDA receptor antagonists are a strategy to counteract excitotoxicity, but often have side effects.
  • Glycine site antagonism of the NMDA receptor emerged as a safer alternative with fewer adverse effects.

Purpose of the Study:

  • To review the development and potential of ACEA 1021, a glycine site antagonist of the NMDA receptor.
  • To assess the existing in vitro and in vivo data supporting ACEA 1021's neuroprotective effects and safety profile.
  • To identify the need for further clinical evaluation of ACEA 1021 for central nervous system (CNS) disorders.

Main Methods:

  • Review of existing literature on NMDA receptor antagonists, specifically glycine site antagonists.
  • Analysis of structure-activity relationship (SAR) studies leading to ACEA 1021.
  • Evaluation of in vitro and in vivo studies on ACEA 1021's neuroprotection and safety.

Main Results:

  • Glycine site antagonism of the NMDA receptor, exemplified by ACEA 1021, offers a promising therapeutic strategy with a potentially improved safety profile compared to other NMDA antagonists.
  • Extensive in vitro and in vivo data support the neuroprotective potential and enhanced safety of ACEA 1021.
  • Limited published clinical pharmacology data currently exists for ACEA 1021.

Conclusions:

  • ACEA 1021 demonstrates significant neuroprotective potential and an improved safety profile based on preclinical data.
  • Further long-term human safety and efficacy studies are essential to fully evaluate ACEA 1021's therapeutic value in acute and chronic CNS disorders.
  • Additional clinical pharmacology data is required to ascertain the true potential of ACEA 1021 in treating neurological and psychiatric conditions.

Related Experiment Videos